

Muneyuki Masuda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5974854/publications.pdf>

Version: 2024-02-01

88
papers

2,124
citations

279798

23
h-index

254184

43
g-index

92
all docs

92
docs citations

92
times ranked

2944
citing authors

#	ARTICLE	IF	CITATIONS
1	Inflammation-based Prognostic Score as a Prognostic Biomarker in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab Therapy. <i>In Vivo</i> , 2022, 36, 907-917.	1.3	10
2	Drug-induced interstitial lung disease in recurrent and/or metastatic head and neck cancer patients treated with cetuximab and/or nivolumab. <i>Oral Oncology</i> , 2021, 113, 105129.	1.5	6
3	PD-L1 expression, tumor-infiltrating lymphocytes, mismatch repair deficiency, EGFR alteration and HPV infection in sinonasal squamous cell carcinoma. <i>Modern Pathology</i> , 2021, 34, 1966-1978.	5.5	17
4	Genetic and transcriptomic analyses in a rare case of HPV-related oropharyngeal squamous cell carcinoma combined with small cell carcinoma. <i>Journal of Physical Education and Sports Management</i> , 2021, 7, mcs.a006102.	1.2	0
5	Is chemoimmunotherapy a game changer in the treatment of locally advanced head and neck squamous cell carcinoma?. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04793.	0.5	1
6	Clinicopathologic Significance of EGFR Mutation and HPV Infection in Sinonasal Squamous Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 108-118.	3.7	27
7	Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab. <i>Oral Oncology</i> , 2020, 101, 104525.	1.5	39
8	Larynx-preserving reconstruction after extended base of the tongue resection. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2020, 73, 740-748.	1.0	1
9	HPV-related Sinonasal Carcinoma. <i>American Journal of Surgical Pathology</i> , 2020, 44, 305-315.	3.7	37
10	Clinical outcome in recurrent and/or metastatic head and neck cancer patients after discontinuation of nivolumab monotherapy due to immune-related adverse events. <i>Acta Oto-Laryngologica</i> , 2020, 140, 1043-1048.	0.9	8
11	Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2020, 12, 2299.	3.7	26
12	YAP1 is a potent driver of the onset and progression of oral squamous cell carcinoma. <i>Science Advances</i> , 2020, 6, eaay3324.	10.3	75
13	Optimization of therapeutic strategy for p16 ⁺ positive oropharyngeal squamous cell carcinoma: Multi-institutional observational study based on the national Head and Neck Cancer Registry of Japan. <i>Cancer</i> , 2020, 126, 4177-4187.	4.1	19
14	Genetic landscape of external auditory canal squamous cell carcinoma. <i>Cancer Science</i> , 2020, 111, 3010-3019.	3.9	14
15	Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers. <i>Frontiers in Microbiology</i> , 2019, 10, 1780.	3.5	57
16	Stress-triggered YAP1/SOX2 activation transcriptionally reprograms head and neck squamous cell carcinoma for the acquisition of stemness. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2433-2444.	2.5	12
17	Prognostic value of programmed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas. <i>Oral Oncology</i> , 2019, 90, 30-37.	1.5	43
18	Small Cell Carcinoma in the Head and Neck. <i>Annals of Otolaryngology and Rhinology</i> , 2019, 128, 1006-1012.	1.1	27

#	ARTICLE	IF	CITATIONS
19	Successful management of recurrent adenoid cystic carcinoma in the deep infratemporal fossa by maxillo-orbito-zygomatic approach. <i>Auris Nasus Larynx</i> , 2019, 46, 921-926.	1.2	1
20	How far advanced the application of NGS technology to head and neck cancer?. <i>Japanese Journal of Head and Neck Cancer</i> , 2019, 45, 343-349.	0.1	0
21	Wnt/ β -catenin signal alteration and its diagnostic utility in basal cell adenoma and histologically similar tumors of the salivary gland. <i>Pathology Research and Practice</i> , 2018, 214, 586-592.	2.3	35
22	Transmanubrial Approach for Removing a Head and Neck Tumor Located at the Upper Lateral Mediastinum. <i>Biomedicine Hub</i> , 2018, 2, 1-6.	1.2	2
23	Treatment of Squamous Cell Carcinoma of the Esophagus Synchronously Associated with Head and Neck Cancer. <i>In Vivo</i> , 2018, 31, 909-916.	1.3	6
24	A Clinical Study of 9 Cases of Myoepithelial Carcinoma of the Head And Neck. <i>Journal of Otolaryngology of Japan</i> , 2018, 121, 1366-1372.	0.1	0
25	Massive internal jugular vein tumor thrombus derived from squamous cell carcinoma of the head and neck: two case reports. <i>Oral and Maxillofacial Surgery</i> , 2017, 21, 69-74.	1.3	7
26	Low-grade intraductal carcinoma (low-grade cribriform cystadenocarcinoma) with tumor-associated lymphoid proliferation of parotid gland. <i>Pathology Research and Practice</i> , 2017, 213, 706-709.	2.3	14
27	Utility of chemoradioselection for the optimization of treatment intensity in advanced hypopharyngeal and laryngeal carcinoma. <i>Molecular and Clinical Oncology</i> , 2017, 7, 965-970.	1.0	2
28	Clinical study of squamous cell carcinoma of the thyroid gland. <i>Japanese Journal of Head and Neck Cancer</i> , 2017, 43, 68-75.	0.1	0
29	A case of peritoneal metastasis during treatment for hypopharyngeal squamous cell carcinoma. <i>World Journal of Surgical Oncology</i> , 2016, 14, 265.	1.9	12
30	Combined transcervical and orbitozygomatic approach for the removal of a nasopharyngeal adenocarcinoma. <i>Journal of Otolaryngology of Japan</i> , 2016, 119, 1461-1462.	0.1	0
31	Combined transcervical and orbitozygomatic approach for the removal of a nasopharyngeal adenocarcinoma. <i>Auris Nasus Larynx</i> , 2016, 43, 192-196.	1.2	3
32	A case of hypopharyngeal cancer with stenosis, perforation, and pyogenic spondylitis development after chemoradiotherapy. <i>International Journal of Surgery Case Reports</i> , 2016, 20, 104-108.	0.6	5
33	Availability of Postoperative Radiotherapy and Chemotherapy for Head and Neck Adenoid Cystic Carcinoma. <i>Practica Otologica</i> , 2016, 109, 557-561.	0.0	0
34	A Case of Extramedullary Plasmacytoma of the Parotid Gland. <i>Practica Otologica</i> , 2016, 109, 493-499.	0.0	0
35	Stress-triggered atavistic reprogramming (STAR) addiction: driving force behind head and neck cancer?. <i>American Journal of Cancer Research</i> , 2016, 6, 1149-66.	1.4	9
36	Utility of algorithm-based chemoradioselection in the treatment for advanced hypopharyngeal carcinoma. <i>Head and Neck</i> , 2015, 37, 1290-1296.	2.0	10

#	ARTICLE	IF	CITATIONS
37	Induction of CD44 Variant 9-Expressing Cancer Stem Cells Might Attenuate the Efficacy of Chemoradioselection and Worsens the Prognosis of Patients with Advanced Head and Neck Cancer. PLoS ONE, 2015, 10, e0116596.	2.5	24
38	Dual gain of HER2 and EGFR gene copy numbers impacts the prognosis of carcinoma ex pleomorphic adenoma. Human Pathology, 2015, 46, 1730-1743.	2.0	20
39	The significance of pretreatment SUV (max) in the algorithm of “chemoradioselection” strategy for hypopharyngeal squamous cell carcinoma: a single-center experience. Japanese Journal of Head and Neck Cancer, 2015, 41, 63-68.	0.1	0
40	Prevalence of Human Papillomavirus in Oropharyngeal Cancer: A Multicenter Study in Japan. Oncology, 2014, 87, 173-182.	1.9	73
41	Treatment outcomes in 13 cases of anaplastic thyroid carcinoma: a single-center experience. Japanese Journal of Head and Neck Cancer, 2014, 40, 98-101.	0.1	1
42	A review of primary mucosal malignant melanoma of the head and neck. Japanese Journal of Head and Neck Cancer, 2014, 40, 102-106.	0.1	3
43	Somatic evolution of head and neck cancer " Biological robustness and latent vulnerability. Molecular Oncology, 2013, 7, 14-28.	4.6	18
44	A minimally invasive method to prevent postlaryngectomy major pharyngocutaneous fistula using infrahyoid myofascial flap. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2013, 66, 906-911.	1.0	19
45	Morphological reconstruction of the neopiglottis after hyo&sub&Eglosso&Egpi	1.0	19
46	A case of G-CSF producing hypopharyngeal carcinoma. Japanese Journal of Head and Neck Cancer, 2013, 39, 60-65.	0.1	1
47	Microsurgical free flap transfer in previously irradiated and operated necks: Feasibility and safety. Auris Nasus Larynx, 2012, 39, 496-501.	1.2	15
48	Tracheal reconstruction with a modified infrahyoid myocutaneous flap. Laryngoscope, 2012, 122, 992-996.	2.0	9
49	Usefulness of three-dimensional computed tomography (3DCT) in skull-based surgery. Journal of Japan Society for Head and Neck Surgery, 2012, 22, 155-162.	0.0	0
50	Thymidylate synthase expression as a predictor of clinical response to 5-fluorouracil-based chemoradiotherapy in patients with maxillary sinus squamous cell carcinoma. Auris Nasus Larynx, 2011, 38, 387-391.	1.2	1
51	Mandible preserving pull-through oropharyngectomy for advanced oropharyngeal cancer: A pilot study. Auris Nasus Larynx, 2011, 38, 392-397.	1.2	22
52	Chemoprevention of Head and Neck Cancer by Green Tea Extract: EGCG"The Role of EGFR Signaling and &Eg Lipid Raft&Eg. Journal of Oncology, 2011, 2011, 1-7.	1.3	42
53	Cancer chemoprevention with green tea catechins by targeting receptor tyrosine kinases. Molecular Nutrition and Food Research, 2011, 55, 832-843.	3.3	105
54	Head and neck reconstruction using infrahyoid myocutaneous flap. Japanese Journal of Head and Neck Cancer, 2011, 37, 126-131.	0.1	2

#	ARTICLE	IF	CITATIONS
55	Glosso-valleculo-epiglottectomy for a patient with recurrent cancer at the base of the tongue resection and reconstruction for recovery of morphology and function. Japanese Journal of Head and Neck Cancer, 2011, 37, 411-416.	0.1	2
56	Roles of neck dissection in multidisciplinary treatment -therapeutic efficacy of organ-preserving and less-extensive dissection-. Japanese Journal of Head and Neck Cancer, 2011, 37, 97-103.	0.1	0
57	Human papillomavirus in oropharyngeal squamous cell carcinoma-A multicenter prospective study in Japan-. Japanese Journal of Head and Neck Cancer, 2011, 37, 398-404.	0.1	3
58	Relative level of thymidylate synthase mRNA expression in primary tumors and normal tissues predicts survival of patients with oral tongue squamous cell carcinoma. European Archives of Oto-Rhino-Laryngology, 2010, 267, 581-586.	1.6	2
59	A case of laryngeal carcinoma in a young adult with dyskeratosis congenita. International Journal of Clinical Oncology, 2010, 15, 428-432.	2.2	6
60	A Critical Role of c-Cbl-Interacting Protein of 85 kDa in the Development and Progression of Head and Neck Squamous Cell Carcinomas through the Ras-ERK Pathway. Neoplasia, 2010, 12, 789-IN4.	5.3	27
61	Correlations between Thymidylate Synthase Expression and Chemosensitivity to 5-Fluorouracil, Cell Proliferation and Clinical Outcome in Head and Neck Squamous Cell Carcinoma. Chemotherapy, 2009, 55, 36-41.	1.6	23
62	The role of dihydropyrimidine dehydrogenase expression in resistance to 5-fluorouracil in head and neck squamous cell carcinoma cells. Oral Oncology, 2009, 45, 141-147.	1.5	15
63	A case of primary Hodgkin's lymphoma of the parotid gland. Auris Nasus Larynx, 2008, 35, 440-442.	1.2	8
64	Signal transducers and activators of transcription 3 up-regulates vascular endothelial growth factor production and tumor angiogenesis in head and neck squamous cell carcinoma. Oral Oncology, 2007, 43, 785-790.	1.5	31
65	Expression of laminin 5 basement membrane components in invading and recurring adenoid cystic carcinoma of the head and neck. Auris Nasus Larynx, 2006, 33, 167-172.	1.2	7
66	Diffuse expression of laminin β 2 chain in disseminating and infiltrating cancer cells indicates a highly malignant state in advanced tongue cancer. Oral Oncology, 2006, 42, 72-75.	1.5	19
67	Role of squamous cell carcinoma antigen 1 expression in the invasive potential of head and neck squamous cell carcinoma. Head and Neck, 2006, 28, 24-30.	2.0	18
68	Effects of a novel NF- κ B inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines. Head and Neck, 2006, 28, 158-165.	2.0	23
69	Sulindac Sulfide and Exisulind Inhibit Expression of the Estrogen and Progesterone Receptors in Human Breast Cancer Cells. Clinical Cancer Research, 2006, 12, 3478-3484.	7.0	13
70	Clinical value of serum squamous cell carcinoma antigen in the management of sinonasal inverted papilloma. Head and Neck, 2005, 27, 44-48.	2.0	26
71	The effect of cyclin D1 overexpression in human head and neck cancer cells. European Archives of Oto-Rhino-Laryngology, 2005, 262, 379-383.	1.6	9
72	Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells. Journal of Cancer Research and Clinical Oncology, 2004, 130, 567-73.	2.5	71

#	ARTICLE	IF	CITATIONS
73	Cyclin D1 expression does not effect cell proliferation in adenoid cystic carcinoma of the salivary gland. <i>European Archives of Oto-Rhino-Laryngology</i> , 2004, 261, 526-530.	1.6	17
74	Irradiation impairment of umami taste in patients with head and neck cancer. <i>Auris Nasus Larynx</i> , 2004, 31, 401-406.	1.2	67
75	Organ presevation by chemoradiotherapy (FAR regimen) and operational pitfalls for patients with hypopharyngeal carcinoma. <i>Journal of Japan Society for Head and Neck Surgery</i> , 2004, 14, 175-182.	0.0	0
76	A MEDICAL TEAM TREATMENT FOR HEAD AND NECK CANCER WITH AN EMPHASIS ON HISTOLOGICAL EVALUATION. <i>Japanese Journal of Head and Neck Cancer</i> , 2004, 30, 395-400.	0.1	0
77	Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells. <i>Clinical Cancer Research</i> , 2003, 9, 3486-91.	7.0	120
78	Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. <i>Journal of Experimental Therapeutics and Oncology</i> , 2002, 2, 350-359.	0.5	213
79	?FAR? chemoradiotherapy improves laryngeal preservation rates in patients with T2N0 glottic carcinoma. <i>Head and Neck</i> , 2002, 24, 637-642.	2.0	28
80	The Roles of JNK1 and Stat3 in the Response of Head and Neck Cancer Cell Lines to Combined Treatment with All trans-retinoic Acid and 5-Fluorouracil. <i>Japanese Journal of Cancer Research</i> , 2002, 93, 329-339.	1.7	44
81	Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. <i>Cancer Research</i> , 2002, 62, 3351-5.	0.9	298
82	Decreased CD44H expression in early-stage tongue carcinoma associates with late nodal metastases following interstitial brachytherapy. <i>Head and Neck</i> , 2000, 22, 662-665.	2.0	36
83	Expression of bcl-2-, p53, and Ki-67 and outcome of patients with primary nasopharyngeal carcinomas following DNA-damaging treatment. , 1998, 20, 640-644.		24
84	p53 and bcl-2 expression and argyrophilic nucleolar organizer regions in patients with malignant maxillary sinus tumours. <i>Journal of Laryngology and Otology</i> , 1997, 111, 38-42.	0.8	2
85	P53 expression in laryngeal carcinoma and maxillary sinus carcinoma and its relationship whit apoptosis.. <i>Japanese Jornal of Head and Neck Cancer</i> , 1997, 23, 595-599.	0.1	0
86	Cyclin D1 overexpression in primary hypopharyngeal carcinomas. , 1996, 78, 390-395.		73
87	Cyclin D1 overexpression in primary hypopharyngeal carcinomas. <i>Cancer</i> , 1996, 78, 390-395.	4.1	5
88	Roles of Therapeutic Selective Neck Dissection in Multidisciplinary Treatment. , 0, , .		2